Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis
- 1 December 2020
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 191 (5), 673-681
- https://doi.org/10.1111/bjh.16697
Abstract
Immunoglobulin light-chain (AL) amyloidosis is a clonal plasma cell disorder characterised by production and deposition of misfolded monoclonal light chains in vital organs with potential to cause irreversible organ damage. The treatment of AL amyloidosis has evolved along the lines of multiple myeloma (MM) owing to clonal plasma cells being at the root of both disease processes. Treatment with melphalan and autologous haematopoietic cell transplantation, as well as proteasome inhibitors and immunomodulatory agents, are the standard of care for AL amyloidosis. While these treatment modalities are highly effective against the neoplastic plasma cells, patients often relapse and those with advanced disease may be unable to tolerate these treatments due to side-effects. Immunotherapy with monoclonal antibodies, bispecific antibodies, antibody-drug conjugates and chimeric antigen receptor T cells have revolutionised the treatment armamentarium for MM. These novel immunotherapy agents are in the early phases of evaluation and clinical development for patients with AL amyloidosis. The present review aims to discuss the role of novel immunotherapies currently in development and their potential for use in the treatment of AL amyloidosis.This publication has 83 references indexed in Scilit:
- AL Amyloid Imaging and Therapy with a Monoclonal Antibody to a Cryptic Epitope on Amyloid FibrilsPLOS ONE, 2012
- Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialBlood, 2012
- Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosisBlood, 2012
- Radioimmunodetection of amyloid deposits in patients with AL amyloidosisBlood, 2010
- Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosisBritish Journal of Haematology, 2010
- Predictors of survival in patients with systemic light‐chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasoneBritish Journal of Haematology, 2008
- Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instabilityBlood, 2008
- Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple MyelomaAmerican Journal of Clinical Pathology, 2004
- Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosisNature, 2002
- Amyloid P component. A critical reviewAmyloid, 1997